Exagen Inc. (NASDAQ: XGN) reported Q1 EPS of ($0.17), $0.05 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $17.31 million versus the consensus estimate of $16.41 million.

GUIDANCE:

Exagen Inc. sees FY 2026 revenue of $70-73 million, versus the consensus of $71.27 million.

For earnings history and earnings-related data on Exagen Inc. (XGN) click here.